Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
LifeSprout offers revolutionary products for soft tissue replacement and regeneration
ArcherDX is a biotechnology firm specializing in cancer research.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.
Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.
inui Health is a consumer medical diagnostics company that provides urinalysis at home via smartphone.
Scioderm, a clinical stage pharmaceutical company, develops topical products for the treatment of chronic skin diseases.
Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.
Redmile Group has invested in 105 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Redmile Group's top investment sectors include Biotechnology, Health Care, Medical, Genetics, Biopharma. The firm invests across 16 different industry categories.
Among tracked funding rounds, Aurinia Pharmaceuticals received $200.0M in a Post Ipo Equity round. Redmile Group's total known invested capital is $12.6B.
Redmile Group's average investment size is $119.9M across its portfolio of 105 companies.
Recent Redmile Group portfolio additions include Aurinia Pharmaceuticals, Atreca, Lifesprout. These companies were founded in 2020 or later.